Overview

uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Status:
Terminated
Trial end date:
2019-10-11
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / CT molecular imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Rigshospitalet, Denmark
Treatments:
Radium Ra 223 dichloride
Succinylcholine
Criteria
Inclusion Criteria:

- Metastatic castration resistant prostate cancer

- Approved to receive Radium-223 therapy

- Written and oral consent

Exclusion Criteria:

- Lack of communication skills

- Other known malignant disease

- Known allergy towards IMP

- Severe claustrophobia

- If a participant exhibits allergic reaction i the IMP, the participant will be
excluded from further participation in the study